Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

BACKGROUND: Second-line treatment for urothelial carcinoma (UC) patients is used if progression or failure after platinum-based chemotherapy occurs or if patients are cisplatin-unfit. However, there is still no widely accepted treatment strategy. We aimed to analyze the effectiveness and safety of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huitao, Liu, Jianhe, Fang, Kewei, Ke, Changxing, Jiang, Yongming, Wang, Guang, Yang, Tongxin, Chen, Tao, Shi, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888906/
https://www.ncbi.nlm.nih.gov/pubmed/31791304
http://dx.doi.org/10.1186/s12894-019-0560-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888906/
https://www.ncbi.nlm.nih.gov/pubmed/31791304
http://dx.doi.org/10.1186/s12894-019-0560-7

Ejemplares similares